13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001766721
Total reported value
$471.6M
$471.6M
15 檔
43.7%
During the Q2 2024 filing period, Aisling Capital Management LP (CIK: 0001766721) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $471.6M across 15 reported positions.
During Q2 2024, Aisling Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 66.52% | -6.87% | — | |
| 2 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 9.11% | -0.36% | — | |
| 3 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 6.98% | — | — | |
| 4 | ✓ | Elevation Oncology Inc | Stock-Other | 3.31% | — | — | |
| 5 | NUVB | Nuvation Bio Inc | Stock-Other | 3.21% | — | — | |
| 6 | CMPS | Compass Pathways PLC | Stock-Other | 2.52% | +2.64% | — | |
| 7 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.38% | +2.61% | — | |
| 8 | BMEA | Biomea Fusion Inc | Stock-Other | 1.56% | -0.02% | — | |
| 9 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 1.32% | — | — | |
| 10 | CALC | Calcimedica Inc | Stock-Other | 0.89% | — | — | |
| 11 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.74% | +0.01% | — | |
| 12 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.60% | — | — | |
| 13 | ✓ | Reneo Pharmaceuticals Inc | Stock-Other | 0.58% | — | — | |
| 14 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.21% | +0.15% | — | |
| 15 | RYI | Viracta Therapeutics Inc | Stock-Other | 0.07% | — | — |
According to official SEC Form 13F filings, Aisling Capital Management LP reported a total U.S. public equity portfolio value of $471.6M across 15 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BBIO, SNDX, VRNA) accounted for 43.7% of total reported equity market value during Q2 2024.
During Q2 2024, Aisling Capital Management LP's top holdings by market value included BBIO (66.5%)、SNDX (9.1%)、VRNA (7.0%). The largest single position, BBIO, represented 66.5% of total portfolio value.
In Q2 2024, Aisling Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.